From infectious disease to oncology: translating a novel glycan target into a ‘pan-cancer’ ADC

“We recently obtained the first data ... which demonstrates that the antibody reaches the tumors to a significant extent with very limited off-target binding.”Lauren Coyle, Editor, Bioconjugate Insights, speaks with Ali Salanti, Professor, University of Copenhagen, and CEO, Var2 Pharma, about the development of a new monovalent ADC with broad anti-tumor activity – from a serendipitous discovery to preparing for clinical trials.